Gemigliptin (rINN) previously identified as LC15-0444 is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It is well known that glucose lowering effects of DPP-4 inhibitors are mainly mediated by GLP-1 and gastric inhibitory polypeptide (GIP) incretin hormones which are inactivated by DPP-4.Gemigliptin was initially developed solely by LG Life Sciences. In 2010 Double-Crane Pharmaceutical Co.
This page contains content from the copyrighted Wikipedia article "Gemigliptin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
.svg?width=300)